Prostate cancer: to screen or not to screen?

The Lancet Oncology
David Neal, J L Donovan

Abstract

The aim of screening is to identify cancers that are potentially curable; before a programme can be introduced, it must satisfy the requirement that it does more good than harm, particularly in terms of survival and quality of life. Prostate cancer is a common disease in older men and presents a significant burden to health services. Prostatic tumours range from small slow-growing lesions to aggressive tumours that metastasise rapidly, but because the natural history of prostate cancer is poorly understood, there is controversy about which screen-detected lesions will become clinically significant. Current methods of screening involve measurement of serum prostate specific antigen, followed by transrectal ultrasound scanning and biopsy, but these lack adequate specificity and sensitivity. There are three major treatment options for localised disease: radical prostatectomy, radical radiotherapy, and monitoring with treatment if required. There is no randomised controlled trial evidence to suggest a survival advantage of any of these treatments, and each has risks. There is intense speculation about future developments in diagnostic testing, molecular markers of progression, and early chemoprevention, but the central question tha...Continue Reading

References

Jan 1, 1990·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·O M JensenH Renard
Jan 1, 1990·The Prostate·S M FinchamC Wijayasinghe
Mar 23, 1984·JAMA : the Journal of the American Medical Association·D CadmanD Sackett
Nov 1, 1993·Annals of Internal Medicine·B S KramerJ K Gohagan
Oct 1, 1996·British Journal of Urology·P J McCahyD E Neal
Feb 22, 1997·BMJ : British Medical Journal·S Stewart-Brown, A Farmer
Apr 5, 1997·BMJ : British Medical Journal·S H Woolf
Jun 1, 1997·The Journal of Urology·H B CarterJ I Epstein
Jan 1, 1997·World Journal of Urology·H B Carter, J I Epstein
May 23, 1998·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·A M Wolf, J B Schorling
Jul 27, 1999·Archives of Family Medicine·R J VolkS J Spann
Oct 16, 1999·American Journal of Epidemiology·R M MerrillR A Stephenson
Feb 16, 2000·Lancet·P C Gøtzsche, O Olsen
Feb 25, 2000·The Journal of Urology·F H SchröderR Kranse
Jul 7, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·D E NealJ L Donovan
Jul 7, 2000·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·W HorningerG Bartsch

❮ Previous
Next ❯

Citations

Mar 7, 2012·Cancer Letters·Karen ChiamTina Bianco-Miotto
Mar 28, 2003·Lancet·Ashesh B Jani, Samuel Hellman
Jan 5, 2002·American Journal of Preventive Medicine·Robert J Volk, Alvah R Cass
Dec 21, 2002·Asia Pacific Journal of Clinical Nutrition·Graeme P Young, Richard K Le Leu
Oct 5, 2002·BMJ : British Medical Journal·Alison ChappleAnn McPherson
Dec 18, 2002·BMJ : British Medical Journal·Samuel T Bauer, Elizabeth M Shadigian
Feb 5, 2009·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Halcyon G Skinner, Gary G Schwartz
Apr 4, 2003·Lancet·Stephen FrankelDavid Neal
Mar 11, 2004·Journal of General Internal Medicine·Vickie L ShaversAngela Fahey
Jun 9, 2016·Journal of the National Medical Association·William N MkantaNabih R Asal
Jun 3, 2009·Brain, Behavior, and Immunity·Emma L TurnerKavita Vedhara
Nov 16, 2004·BJU International·Roger Kirby, John Fitzpatrick
Dec 23, 2008·Molecular Nutrition & Food Research·Peter D BaadeLauren J Krnjacki
Sep 24, 2004·Annals of Epidemiology·Ali ShamseddineUNKNOWN Lebanese Cancer Epidemiology Group
Nov 11, 2005·Archives of Gerontology and Geriatrics·Salvatore RannoMariano Malaguarnera
Oct 13, 2006·BJU International·Gerard J GormleyAnna T Gavin
Jan 5, 2008·Qualitative Health Research·Alison ChappleAnn McPherson
Jan 8, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Howard L ParnesLeslie G Ford
Apr 3, 2003·Nature Reviews. Cancer·Michael N Pollak, William D Foulkes
May 18, 2001·Nature·B A Ponder
Dec 14, 2004·Prostate Cancer and Prostatic Diseases·R Kirby, J W Moul
Apr 25, 2000·Journal of Gerontological Nursing·D W BrunerV Burggraf
Apr 23, 2009·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Heiko MüllerHermann Brenner
Apr 18, 2007·The Medical Journal of Australia·Philippe CarrièreMonika Janda

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

BMJ : British Medical Journal
P Abrams, A Wein
European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
F H Schröder
© 2022 Meta ULC. All rights reserved